
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11233107/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 2011, 10, 52-77.	10.4	1,767
2	Large recurrent microdeletions associated with schizophrenia. Nature, 2008, 455, 232-236.	27.8	1,619
3	Common variants conferring risk of schizophrenia. Nature, 2009, 460, 744-747.	27.8	1,572
4	Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nature Genetics, 2008, 40, 1053-1055.	21.4	977
5	Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 2000, 59, S5-S30.	4.1	741
6	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	7.2	685
7	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. World Journal of Biological Psychiatry, 2008, 9, 248-312.	2.6	661
8	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 2011, 10, 138-151.	10.4	631
9	Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. NeuroImage, 2004, 22, 83-94.	4.2	555
10	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry, 2012, 13, 318-378.	2.6	498
11	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World Journal of Biological Psychiatry, 2013, 14, 334-385.	2.6	480
12	Hippocampal Changes in Patients With a First Episode of Major Depression. American Journal of Psychiatry, 2002, 159, 1112-1118.	7.2	464
13	Social Functioning in Depression. Journal of Clinical Psychiatry, 2000, 61, 268-275.	2.2	464
14	Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics, 2009, 18, 988-996.	2.9	424
15	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	12.3	390
16	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383
17	Use of Neuroanatomical Pattern Classification to Identify Subjects in At-Risk Mental States of Psychosis and Predict Disease Transition. Archives of General Psychiatry, 2009, 66, 700.	12.3	382
18	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophrenia Bulletin, 2014, 40, 1140-1153.	4.3	369

#	Article	IF	CITATIONS
19	Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia. American Journal of Psychiatry, 2002, 159, 1029-1034.	7.2	366
20	Association of the Brain-Derived Neurotrophic Factor Val66Met Polymorphism With Reduced Hippocampal Volumes in Major Depression. Archives of General Psychiatry, 2007, 64, 410.	12.3	357
21	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry, 2013, 14, 154-219.	2.6	344
22	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry, 2013, 14, 2-44.	2.6	343
23	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World Journal of Biological Psychiatry, 2007, 8, 67-104.	2.6	335
24	Depression-Related Variation in Brain Morphology Over 3 Years. Archives of General Psychiatry, 2008, 65, 1156.	12.3	329
25	Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice, 2012, 16, 77-84.	2.4	327
26	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World Journal of Biological Psychiatry, 2010, 11, 81-109.	2.6	322
27	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder. World Journal of Biological Psychiatry, 2002, 3, 5-43.	2.6	311
28	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World Journal of Biological Psychiatry, 2009, 10, 85-116.	2.6	302
29	Enlargement of the amygdala in patients with a first episode of major depression. Biological Psychiatry, 2002, 51, 708-714.	1.3	285
30	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Research, 1999, 88, 163-171.	3.3	274
31	Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. Archives of Neurology, 2002, 59, 1267.	4.5	256
32	Lithium Trial in Alzheimer's Disease. Journal of Clinical Psychiatry, 2009, 70, 922-931.	2.2	252
33	Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ: British Medical Journal, 2003, 326, 200-201.	2.3	243
34	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry, 2005, 6, 132-191.	2.6	242
35	Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biological Psychiatry, 2003, 53, 338-344.	1.3	238
36	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research, 2010, 121, 118-124.	2.0	227

#	Article	IF	CITATIONS
37	A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities. Biological Psychiatry, 2006, 59, 721-729.	1.3	219
38	Response and remission criteria in major depression – A validation of current practice. Journal of Psychiatric Research, 2010, 44, 1063-1068.	3.1	219
39	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain, 2005, 128, 2626-2644.	7.6	213
40	Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. Journal of Psychiatry and Neuroscience, 2008, 33, 423-30.	2.4	211
41	Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophrenia Research, 2001, 48, 125-136.	2.0	197
42	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. World Journal of Biological Psychiatry, 2006, 7, 5-40.	2.6	194
43	Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase Isoform (TPH2) gene in suicide victims. Biological Psychiatry, 2004, 56, 581-586.	1.3	193
44	Hippocampal and Amygdala Changes in Patients With Major Depressive Disorder and Healthy Controls During a 1-Year Follow-Up. Journal of Clinical Psychiatry, 2004, 65, 492-499.	2.2	188
45	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. NeuroImage, 2007, 38, 13-24.	4.2	185
46	White matter microstructure underlying default mode network connectivity in the human brain. NeuroImage, 2010, 49, 2021-2032.	4.2	185
47	Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Review of Neurotherapeutics, 2008, 8, 527-536.	2.8	184
48	Early detection and secondary prevention of psychosis: facts and visions*. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 117-128.	3.2	183
49	Reduced hippocampal volume correlates with executive dysfunctioning in major depression. Journal of Psychiatry and Neuroscience, 2006, 31, 316-23.	2.4	178
50	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters, 2000, 287, 187-190.	2.1	176
51	Childhood Stress, Serotonin Transporter Gene and Brain Structures in Major Depression. Neuropsychopharmacology, 2010, 35, 1383-1390.	5.4	175
52	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research, 1999, 88, 107-117.	3.3	174
53	Partial Response and Nonresponse to Antidepressant Therapy. Journal of Clinical Psychiatry, 2002, 63, 826-837.	2.2	170
54	Progression of Corpus Callosum Atrophy in Alzheimer Disease. Archives of Neurology, 2002, 59, 243.	4.5	167

#	Article	IF	CITATIONS
55	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. Journal of Psychiatric Research, 2009, 43, 1262-1271.	3.1	167
56	Structural correlates of psychopathological symptom dimensions in schizophrenia: A voxel-based morphometric study. NeuroImage, 2008, 39, 1600-1612.	4.2	166
57	Reduced Hippocampal Volumes Associated With the Long Variant of theSerotonin Transporter Polymorphism in Major Depression. Archives of General Psychiatry, 2004, 61, 177.	12.3	164
58	Functional Connectivity Bias of the Orbitofrontal Cortex in Drug-Free Patients with Major Depression. Biological Psychiatry, 2010, 67, 161-167.	1.3	164
59	A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biological Psychiatry, 2003, 54, 34-39.	1.3	162
60	Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. NeuroImage, 2005, 28, 49-58.	4.2	162
61	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neurolmage, 2007, 34, 985-995.	4.2	162
62	Reliability and plasticity of response inhibition and interference control. Brain and Cognition, 2013, 81, 82-94.	1.8	162
63	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. World Journal of Biological Psychiatry, 2002, 3, 115-124.	2.6	161
64	Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: Preliminary results of a dynamic [123I] IBZM SPECT study. Journal of Psychiatric Research, 2006, 40, 307-314.	3.1	161
65	Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. International Journal of Neuropsychopharmacology, 2014, 17, 859-869.	2.1	161
66	Correlation of Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 With Rates of Hippocampal Atrophy in Alzheimer Disease. Archives of Neurology, 2005, 62, 770.	4.5	158
67	Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. Journal of Psychiatric Research, 2007, 41, 168-173.	3.1	157
68	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Journal of Biological Psychiatry, 2002, 3, 171-199.	2.6	155
69	The serotonin syndrome scale: first results on validity. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 96-103.	3.2	154
70	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015. World Journal of Biological Psychiatry, 2015, 16, 76-95.	2.6	153
71	Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 2002, 52, 253-256.	5.3	152
72	Does early improvement triggered by antidepressants predict response/remission? — Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of Affective Disorders, 2009, 115, 439-449.	4.1	150

#	Article	IF	CITATIONS
73	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. American Journal of Psychiatry, 2015, 172, 617-629.	7.2	150
74	The World Federation of Socleties of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World Journal of Biological Psychiatry, 2003, 4, 5-13.	2.6	148
75	Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2Receptor Gene. American Journal of Psychiatry, 2001, 158, 802-804.	7.2	144
76	Prediction of treatment response in major depression: Integration of concepts. Journal of Affective Disorders, 2007, 98, 215-225.	4.1	142
77	A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 1995, 245, 45-49.	3.2	139
78	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. Schizophrenia Bulletin, 2012, 38, 1234-1246.	4.3	139
79	Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depression and Anxiety, 2007, 24, 185-195.	4.1	138
80	Genetic variations in tryptophan hydroxylase in suicidal behavior. Biological Psychiatry, 2003, 54, 465-473.	1.3	137
81	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	1.7	137
82	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World Journal of Biological Psychiatry, 2007, 8, 212-244.	2.6	136
83	The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. Human Brain Mapping, 2011, 32, 1349-1362.	3.6	136
84	Ageâ€related cortical grey matter reductions in nonâ€demented Down's syndrome adults determined by MRI with voxelâ€based morphometry. Brain, 2004, 127, 811-824.	7.6	135
85	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.7	135
86	Single-trial coupling of EEG and fMRI reveals the involvement of early anterior cingulate cortex activation in effortful decision making. NeuroImage, 2008, 42, 158-168.	4.2	133
87	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. Journal of Psychiatric Research, 2011, 45, 309-321.	3.1	133
88	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain, 2015, 138, 2059-2073.	7.6	132
89	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions. World Journal of Biological Psychiatry. 2002. 3. 69-86.	2.6	131
90	Psychosis Susceptibility Gene ZNF804A and Cognitive Performance in Schizophrenia. Archives of General Psychiatry, 2010, 67, 692.	12.3	129

#	Article	IF	CITATIONS
91	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World Journal of Biological Psychiatry, 2018, 19, 2-58.	2.6	128
92	The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophrenia Research, 2003, 62, 37-44.	2.0	127
93	Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group. Journal of Clinical Psychopharmacology, 2001, 21, 59-65.	1.4	126
94	COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 14-22.	3.2	126
95	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of â€`subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. International Clinical Psychopharmacology, 2010, 25, 277-287.	1.7	126
96	Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Research, 2006, 141, 89-101.	3.3	125
97	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. World Journal of Biological Psychiatry, 2004, 5, 120-135.	2.6	124
98	Factor structure and external validity of the PANSS revisited. Schizophrenia Research, 2006, 82, 213-223.	2.0	124
99	Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early—and Additional Memory Dysfunction in the Late—Prodromal State. Schizophrenia Bulletin, 2011, 37, 861-873.	4.3	124
100	Associations between trait impulsivity and prepotent response inhibition. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 1016-1032.	1.3	124
101	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry, 2007, 191, s88-s95.	2.8	122
102	Early Recognition and Disease Prediction in the At-Risk Mental States for Psychosis Using Neurocognitive Pattern Classification. Schizophrenia Bulletin, 2012, 38, 1200-1215.	4.3	121
103	Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. International Journal of Neuropsychopharmacology, 2011, 14, 405-412.	2.1	120
104	Syndromes and Phenomenological Subtypes Underlying Acute Mania: A Factor Analytic Study of 576 Manic Patients. American Journal of Psychiatry, 2002, 159, 968-974.	7.2	118
105	Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. General Hospital Psychiatry, 2004, 26, 190-198.	2.4	116
106	Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. International Journal of Psychiatry in Clinical Practice, 2017, 21, 166-176.	2.4	115
107	Substance P serum levels are increased in major depression: preliminary results. Biological Psychiatry, 2003, 53, 538-542.	1.3	113
108	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 1-48.	3.2	113

#	Article	IF	CITATIONS
109	Management of the Negative Symptoms of Schizophrenia. CNS Drugs, 2003, 17, 793-823.	5.9	111
110	Electroconvulsive therapy and its different indications. Dialogues in Clinical Neuroscience, 2008, 10, 105-117.	3.7	111
111	Association of an Interleukin-1 ^{î2} Genetic Polymorphism With Altered Brain Structure in Patients With Schizophrenia. American Journal of Psychiatry, 2001, 158, 1316-1319.	7.2	110
112	Reduced Early Auditory Evoked Gamma-Band Response in Patients with Schizophrenia. Biological Psychiatry, 2010, 67, 224-231.	1.3	110
113	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology, 2002, 39, 175-181.	2.4	109
114	Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biological Psychiatry, 2003, 54, 1406-1413.	1.3	108
115	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. Journal of Neurology, 2006, 253, 794-800.	3.6	106
116	Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophrenia Research, 2007, 97, 254-263.	2.0	106
117	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16. 142-170.	2.6	106
118	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology, 2005, 20, 121-130.	1.7	105
119	Acute prefrontal rTMS increases striatal dopamine to a similar degree as d-amphetamine. Psychiatry Research - Neuroimaging, 2007, 156, 251-255.	1.8	103
120	Orbitofrontal volume reductions during emotion recognition in patients with major depression. Journal of Psychiatry and Neuroscience, 2010, 35, 311-320.	2.4	101
121	Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression Relation between Efficacy and Stimulation Intensity. Neuropsychopharmacology, 2002, 27, 638-45.	5.4	98
122	Anger- and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. Journal of Affective Disorders, 2006, 96, 75-81.	4.1	98
123	Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology, 2009, 24, 111-118.	1.7	98
124	Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophrenia Research, 2009, 113, 210-217.	2.0	97
125	Relation of Corpus Callosum and Hippocampal Size to Age in Nondemented Adults With Down's Syndrome. American Journal of Psychiatry, 2003, 160, 1870-1878.	7.2	96
126	Amygdala Volume and Depressive Symptoms in Patients With Borderline Personality Disorder. Biological Psychiatry, 2006, 60, 302-310.	1.3	96

#	Article	IF	CITATIONS
127	Silexan in anxiety disorders: Clinical data and pharmacological background. World Journal of Biological Psychiatry, 2018, 19, 412-420.	2.6	96
128	Title is missing!. , 1997, 174, 255-259.		95
129	Systematic of psychiatric disorders between categorical and dimensional approaches. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 48-73.	3.2	95
130	Cognitive functioning in euthymic bipolar I and bipolar II patients. Bipolar Disorders, 2008, 10, 877-887.	1.9	95
131	Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. World Journal of Biological Psychiatry, 2008, 9, 102-114.	2.6	95
132	Maternally Derived Microduplications at 15q11-q13: Implication of Imprinted Genes in Psychotic Illness. American Journal of Psychiatry, 2011, 168, 408-417.	7.2	95
133	Should the PANSS Be Rescaled?. Schizophrenia Bulletin, 2010, 36, 455-460.	4.3	94
134	Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. Journal of Affective Disorders, 2001, 63, 79-83.	4.1	91
135	Digitized analysis of handwriting and drawing movements in healthy subjects: methods, results and perspectives. Journal of Neuroscience Methods, 1999, 90, 157-169.	2.5	90
136	Discriminant power of combined cerebrospinal fluid Ï,, protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1. Brain Research, 1999, 823, 104-112.	2.2	90
137	Auditory cortex and anterior cingulate cortex sources of the early evoked gamma-band response: Relationship to task difficulty and mental effort. Neuropsychologia, 2007, 45, 2294-2306.	1.6	88
138	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. World Journal of Biological Psychiatry, 2011, 12, 160-187.	2.6	88
139	Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Research, 2003, 119, 63-79.	3.3	87
140	Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 103-118.	2.6	86
141	Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. British Journal of Psychiatry, 2009, 195, 218-226.	2.8	85
142	Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnestic mild cognitive impairment. Human Brain Mapping, 2009, 30, 2098-2119.	3.6	85
143	Comparison of racemic ketamine and <i>S</i> -ketamine in treatment-resistant major depression: Report of two cases. World Journal of Biological Psychiatry, 2009, 10, 241-244.	2.6	85
144	The Schizophrenia Risk Allele C of the <i>TCF4</i> rs9960767 Polymorphism Disrupts Sensorimotor Gating in Schizophrenia Spectrum and Healthy Volunteers. Journal of Neuroscience, 2011, 31, 6684-6691.	3.6	85

#	Article	IF	CITATIONS
145	Brainâ€derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 183-190.	1.7	85
146	Rostral Anterior Cingulate Cortex Activity in the Theta Band Predicts Response to Antidepressive Medication. Clinical EEG and Neuroscience, 2007, 38, 78-81.	1.7	84
147	White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease1. Journal of Alzheimer's Disease, 2009, 17, 571-583.	2.6	84
148	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1 International Journal of Neuropsychopharmacology, 2015, 18, pyv042.	2.1	84
149	Differentiation of Geriatric Major Depression From Alzheimer's Disease With CSF Tau Protein Phosphorylated at Threonine 231. American Journal of Psychiatry, 2003, 160, 376-379.	7.2	83
150	Do SSRIs or antidepressants in general increase suicidality?. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 3-23.	3.2	83
151	A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology, 2014, 24, 1005-1014.	0.7	83
152	Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophrenia Research, 2003, 64, 115-124.	2.0	82
153	Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. Psychiatry Research - Neuroimaging, 2007, 154, 157-170.	1.8	82
154	The relevance of â€~mixed anxiety and depression' as a diagnostic category in clinical practice. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 725-736.	3.2	82
155	Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. European Neuropsychopharmacology, 2000, 10, 211-217.	0.7	81
156	Neuronal correlates of emotional processing in patients with major depression. World Journal of Biological Psychiatry, 2009, 10, 202-208.	2.6	81
157	Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. World Journal of Biological Psychiatry, 2009, 10, 6-26.	2.6	80
158	Der Verlauf schizophrener Psychosen. , 1986, , .		80
159	Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. Journal of Affective Disorders, 2004, 78, 149-152.	4.1	79
160	Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia. Psychiatric Services, 2012, 63, 87-90.	2.0	79
161	Relapse Prevention in First-Episode Schizophrenia—Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention. Journal of Clinical Psychiatry, 2011, 72, 205-218.	2.2	79
162	Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1101-1111.	4.8	78

#	Article	IF	CITATIONS
163	Clinical evaluation of negative symptoms in schizophrenia. European Psychiatry, 2007, 22, 380-386.	0.2	78
164	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry, 2011, 12, 2-32.	2.6	77
165	Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 1763-1774.	2.2	76
166	Antipsychotic and antidepressive effects of second generation antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 190-201.	3.2	74
167	Fiber Connections between the Cerebral Cortex and the Corpus Callosum in Alzheimer's Disease: A Diffusion Tensor Imaging and Voxel-Based Morphometry Study. Cerebral Cortex, 2007, 17, 2276-2282.	2.9	74
168	Reduced hippocampal volumes associated with the long variant of the tri―and diallelic serotonin transporter polymorphism in major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1003-1007.	1.7	74
169	The effects of methylphenidate on whole brain intrinsic functional connectivity. Human Brain Mapping, 2014, 35, 5379-5388.	3.6	74
170	Social disability in schizophrenic, schizoaffective and affective disorders 15years after first admission. Schizophrenia Research, 2010, 116, 9-15.	2.0	73
171	Antidepressants and Driving Ability. Journal of Clinical Psychiatry, 2006, 67, 1776-1781.	2.2	73
172	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. European Neuropsychopharmacology, 2010, 20, 346-355.	0.7	72
173	Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 13-20.	3.2	71
174	Clinical predictors of response and remission in inpatients with depressive syndromes. Journal of Affective Disorders, 2011, 133, 137-149.	4.1	71
175	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. Schizophrenia Research, 2002, 56, 87-94.	2.0	70
176	Decreased serum amyloid β1–42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide. Biological Psychiatry, 2005, 57, 813-816.	1.3	70
177	<i>HTR2C</i> and <i>HTR1A</i> gene variants in German and Italian suicide attempters and completers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 291-299.	1.7	70
178	Decreased T cellular immune response in schizophrenic patients. Journal of Psychiatric Research, 2007, 41, 3-7.	3.1	70
179	Dipole localization and test-retest reliability of frequency and duration mismatch negativity generator processes. Brain Topography, 1997, 10, 3-8.	1.8	69
180	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease. Neurobiology of Aging, 2006, 27, 10-15.	3.1	69

#	Article	IF	CITATIONS
181	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. European Neuropsychopharmacology, 1993, 3, 13-21.	0.7	67
182	German research network on schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 321-329.	3.2	67
183	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World Journal of Biological Psychiatry, 2008, 9, 6-23.	2.6	67
184	Molecular Genetic Findings in Suicidal Behavior: What is Beyond the Serotonergic System?. Archives of Suicide Research, 2007, 11, 17-40.	2.3	66
185	Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. International Journal of Neuropsychopharmacology, 2008, 11, 217-28.	2.1	66
186	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. International Clinical Psychopharmacology, 2007, 22, 212-220.	1.7	64
187	Evaluation of the German WPA "Program against stigma and discrimination because of schizophrenia — Open the Doors†Results from representative telephone surveys before and after threeÂyears of antistigma interventions. Schizophrenia Research, 2008, 98, 184-193.	2.0	64
188	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. European Neuropsychopharmacology, 2008, 18, 122-127.	0.7	64
189	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neuroscience Letters, 1997, 228, 143-146.	2.1	63
190	Screening for depression in primary care: Will one or two items suffice?. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 215-23.	3.2	63
191	Temperament and character of suicide attempters. Journal of Psychiatric Research, 2008, 42, 938-945.	3.1	63
192	Is the PANSS used correctly? a systematic review. BMC Psychiatry, 2011, 11, 113.	2.6	63
193	Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neuroscience Letters, 1999, 277, 21-24.	2.1	62
194	Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology, 2006, 187, 86-94.	3.1	62
195	No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. Annals of General Psychiatry, 2013, 12, 26.	2.7	62
196	Drug Treatment of Depression in the 1990s. Drugs, 1996, 52, 625-638.	10.9	61
197	Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice?. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 1-16.	3.2	61
198	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice, 2017, 21, 82-90.	2.4	61

#	Article	IF	CITATIONS
199	Vigabatrin Decreases Cholecystokinin-Tetrapeptide (CCK-4) Induced Panic in Healthy Volunteers. Neuropsychopharmacology, 2001, 25, 699-703.	5.4	59
200	Placebo-controlled studies in depression: necessary, ethical and feasible. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 22-28.	3.2	59
201	Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophrenia Research, 2004, 67, 175-183.	2.0	59
202	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 269-278.	3.2	59
203	The Impact of Antipsychotics on Psychomotor Performance With Regards to Car Driving Skills. Journal of Clinical Psychopharmacology, 2004, 24, 155-160.	1.4	58
204	A Ser9Gly Polymorphism in the Dopamine D3 Receptor Gene (DRD3) and Event-Related P300 Potentials. Neuropsychopharmacology, 2006, 31, 1335-1344.	5.4	58
205	Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 47-53.	3.2	58
206	Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. Schizophrenia Research, 2010, 123, 175-187.	2.0	58
207	P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biological Psychiatry, 1999, 45, 116-126.	1.3	57
208	Is there evidence for negative effects of antidepressants on suicidality in depressive patients?. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 476-496.	3.2	57
209	Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: Hints to a new intermediate phenotype. Journal of Psychiatric Research, 2011, 45, 699-705.	3.1	57
210	Repeated Sâ€ketamine Infusions in Therapy Resistant Depression: A Case Series. Journal of Clinical Pharmacology, 2013, 53, 996-998.	2.0	57
211	Newer and Older Monoamine Oxidase Inhibitors. CNS Drugs, 1995, 3, 145-158.	5.9	56
212	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neuroscience Letters, 1999, 259, 145-148.	2.1	56
213	Risperidone: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 803-818.	1.8	56
214	The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 367-384.	3.2	56
215	Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment, 2007, 3, 219-235.	2.2	56
216	Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?. Journal of Affective Disorders, 2001, 67, 141-146.	4.1	55

#	Article	IF	CITATIONS
217	Influence of trait anxiety on inhibitory control in alcohol-dependent patients: Simultaneous acquisition of ERPs and BOLD responses. Journal of Psychiatric Research, 2008, 42, 734-745.	3.1	55
218	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. International Journal of Neuropsychopharmacology, 2008, 11, 985-97.	2.1	55
219	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Journal of Psychiatric Research, 2011, 45, 234-241.	3.1	55
220	Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans. Cerebral Cortex, 2013, 23, 1179-1189.	2.9	55
221	Pharmacological treatment of negative symptoms in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 567-578.	3.2	55
222	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World Journal of Biological Psychiatry, 2017, 18, 86-119.	2.6	55
223	Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 296-300.	3.2	54
224	Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". European Archives of Psychiatry and Clinical Neuroscience, 2000, 250, 120-132.	3.2	54
225	Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology, 2003, 166, 271-275.	3.1	54
226	Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World Journal of Biological Psychiatry, 2005, 6, 247-263.	2.6	54
227	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Microbial Biotechnology, 2007, 1, 71-78.	1.7	54
228	Neuropsychological impairments predict the clinical course in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 28-34.	3.2	54
229	Association between brain structure and psychometric schizotypy in healthy individuals. World Journal of Biological Psychiatry, 2012, 13, 544-549.	2.6	54
230	Serotonin and Dopamine Transporter Availabilities Correlate with the Loudness Dependence of Auditory Evoked Potentials in Patients with Obsessive-Compulsive Disorder. Neuropsychopharmacology, 2004, 29, 1910-1917.	5.4	53
231	Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 83-93.	3.2	53
232	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 127-137.	3.2	53
233	A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: No role in the genetic predisposition to bipolar affective disorder. Psychiatry Research, 1993, 46, 253-259.	3.3	52
234	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. Brain Research, 1998, 780, 356-359.	2.2	52

#	Article	IF	CITATIONS
235	Region-Specific Corpus Callosum Atrophy Correlates With the Regional Pattern of Cortical Glucose Metabolism in Alzheimer Disease. Archives of Neurology, 1999, 56, 467.	4.5	52
236	Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. Acta Psychiatrica Scandinavica, 2000, 102, 54-57.	4.5	52
237	Digitized analysis of abnormal hand–motor performance in schizophrenic patients. Schizophrenia Research, 2000, 45, 133-143.	2.0	52
238	Pharmacological long-term treatment strategies in first episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 129-140.	3.2	52
239	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: An fMRI study. Psychiatry Research - Neuroimaging, 2008, 163, 248-259.	1.8	52
240	Effectiveness studies: advantages and disadvantages. Dialogues in Clinical Neuroscience, 2011, 13, 199-207.	3.7	52
241	Evidence for beneficial effects of antidepressants on suicidality in depressive patients. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 329-343.	3.2	51
242	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wiener Medizinische Wochenschrift, 2010, 160, 547-556.	1.1	51
243	A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Human Molecular Genetics, 2010, 19, 1379-1386.	2.9	51
244	Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophrenia Research, 2000, 44, 145-150.	2.0	50
245	Repetitive Transcranial Magnetic Stimulation. CNS Drugs, 2003, 17, 383-403.	5.9	50
246	NOSâ€I and â€III gene variants are differentially associated with facets of suicidal behavior and aggressionâ€related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 42-48.	1.7	50
247	Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. Schizophrenia Research, 2016, 173, 159-165.	2.0	50
248	Effectiveness and Safety of Benzodiazepines. Journal of Clinical Psychopharmacology, 1999, 19, 2S-11S.	1.4	50
249	Biochemical Findings of Negative Symptoms in Schizophrenia and Their Putative Relevance to Pharmacological Treatment. Neuropsychobiology, 1994, 30, 160-172.	1.9	49
250	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 432-437.	3.2	49
251	Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression. Current Pharmaceutical Design, 2006, 12, 503-515.	1.9	49
252	Anterior cingulate cortex does not differ between patients with major depression and healthy controls, but relatively large anterior cingulate cortex predicts a good clinical course. Psychiatry Research - Neuroimaging, 2008, 163, 76-83.	1.8	49

#	Article	IF	CITATIONS
253	Functional neural correlates of psychometric schizotypy: An <scp>fMRI</scp> study of antisaccades. Psychophysiology, 2012, 49, 345-356.	2.4	49
254	Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences. World Journal of Biological Psychiatry, 2000, 1, 75-91.	2.6	48
255	P300 subcomponents in obsessive-compulsive disorder. Journal of Psychiatric Research, 2002, 36, 399-406.	3.1	48
256	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. Journal of the Neurological Sciences, 2002, 194, 15-19.	0.6	47
257	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain, 2007, 130, 1745-1758.	7.6	47
258	Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. Drugs, 2007, 67, 1541-1566.	10.9	47
259	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 360-370.	3.2	47
260	Treatment Response in First-episode Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2012, 10, 78-87.	2.0	47
261	The Diagnosis and Treatment of Generalized Anxiety Disorder. Deutsches Ärzteblatt International, 2013, 110, 300-9; quiz 310.	0.9	47
262	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2006, 7, 162-170.	2.6	46
263	Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. Schizophrenia Research, 2010, 123, 160-174.	2.0	46
264	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response?. European Neuropsychopharmacology, 2011, 21, 370-378.	0.7	46
265	Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Psychopathology, 2012, 45, 276-285.	1.5	46
266	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. Journal of Psychiatric Research, 2005, 39, 101-108.	3.1	45
267	Influence of NOS1 on Verbal Intelligence and Working Memory in Both Patients With Schizophrenia and Healthy Control Subjects. Archives of General Psychiatry, 2009, 66, 1045.	12.3	45
268	Therapeutic efficacy of the Ginkgo special extract EGb761 [®] within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. World Journal of Biological Psychiatry, 2019, 20, 173-189.	2.6	45
269	How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. International Journal of Neuropsychopharmacology, 2017, 20, 721-730.	2.1	44
270	The Impact of Reboxetine and Mirtazapine on Driving Simulator Performance and Psychomotor Function in Depressed Patients. Journal of Clinical Psychiatry, 2008, 69, 1880-1886.	2.2	44

#	Article	IF	CITATIONS
271	Atypical neuroleptics: a new approach in the treatment of negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S99-S107.	3.2	43
272	The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. International Journal of Neuropsychopharmacology, 2009, 12, 181.	2.1	43
273	Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: Evidence from a working memory task. Journal of Psychiatric Research, 2009, 43, 1185-1194.	3.1	43
274	Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World Journal of Biological Psychiatry, 2006, 7, 198-222.	2.6	42
275	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. Journal of Psychiatric Research, 2009, 43, 519-525.	3.1	42
276	An early improvement threshold to predict response and remission in first-episode schizophrenia. British Journal of Psychiatry, 2010, 196, 460-466.	2.8	42
277	State of the Art of Drug Treatment of Schizophrenia and the Future Position of the Novel/Atypical Antipsychotics. World Journal of Biological Psychiatry, 2000, 1, 204-214.	2.6	41
278	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2006, 7, 82-90.	2.6	41
279	Selecting Methodologies for the Evaluation of Differences in Time to Response Between Antidepressants. Journal of Clinical Psychiatry, 2002, 63, 694-699.	2.2	41
280	The Impact of Homocysteine Levels on Cognition in Euthymic Bipolar Patients. Journal of Clinical Psychiatry, 2008, 69, 899-906.	2.2	41
281	[I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. Journal of Psychiatry and Neuroscience, 2007, 32, 234-40.	2.4	41
282	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 257, 402-412.	3.2	40
283	Development of DSMâ€V and ICDâ€11: Tendencies and potential of new classifications in psychiatry at the current state of knowledge. Psychiatry and Clinical Neurosciences, 2009, 63, 595-612.	1.8	40
284	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 207-245.	3.2	40
285	Novel Schizophrenia Risk Gene TCF4 Influences Verbal Learning and Memory Functioning in Schizophrenia Patients. Neuropsychobiology, 2011, 63, 131-136.	1.9	40
286	The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 226-231.	3.2	39
287	Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology, 2011, 216, 17-27.	3.1	39
288	Negative Symptoms in Depressed and Schizophrenic Patients. Journal of Clinical Psychiatry, 2003, 64, 954-958.	2.2	39

#	Article	IF	CITATIONS
289	Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depression and Anxiety, 2003, 18, 140-143.	4.1	38
290	Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. , 2003, 116B, 69-71.		38
291	Non-neuroleptic approaches to treating negative symptoms in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 108-116.	3.2	38
292	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. Journal of Psychiatric Research, 2008, 42, 963-970.	3.1	38
293	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 567-575.	3.2	38
294	Tiagabine Improves Panic and Agoraphobia in Panic Disorder Patients. Journal of Clinical Psychiatry, 2001, 62, 656-657.	2.2	38
295	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 183-193.	3.2	37
296	In-vivo analysis of the human planum temporale (PT): does the definition of PT borders influence the results with regard to cerebral asymmetry and correlation with handedness?. Psychiatry Research - Neuroimaging, 2001, 107, 99-115.	1.8	36
297	On the Descriptive Validity of ICD-10 Schizophrenia: Empirical Analyses in the Spectrum of Non-Affective Functional Psychoses. Psychopathology, 2003, 36, 152-159.	1.5	36
298	The Speed of Visual Attention and Motor-Response Decisions in Adult Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2015, 78, 107-115.	1.3	36
299	Risk factors for suicides of inpatients with depressive psychoses. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 141-147.	3.2	35
300	Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S27-S36.	3.2	35
301	Should combined pharmaco- and psychotherapy be offered to depressed patients?. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 99-107.	3.2	35
302	Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease. Journal of Clinical Psychopharmacology, 2009, 29, 147-156.	1.4	35
303	Suicidality as Rare Adverse Event of Antidepressant Medication. Journal of Clinical Psychiatry, 2010, 71, 1239-1307.	2.2	35
304	P300 subcomponents and clinical symptoms in schizophrenia. International Journal of Psychophysiology, 2002, 43, 237-246.	1.0	34
305	Internal capsule size associated with outcome in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 278-283.	3.2	34
306	One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Research, 2012, 198, 378-385.	3.3	34

#	Article	IF	CITATIONS
307	Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 59-68.	3.2	34
308	The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. Journal of Psychopharmacology, 2016, 30, 40-47.	4.0	34
309	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	2.0	34
310	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. International Journal of Methods in Psychiatric Research, 2018, 27, .	2.1	34
311	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. International Journal of Neuropsychopharmacology, 2018, 21, 814-821.	2.1	34
312	Effects of Haloperidol and Atypical Neuroleptics on Psychomotor Performance and Driving Ability in Schizophrenic Patients. Neuropsychobiology, 2003, 47, 212-218.	1.9	33
313	Do effectiveness ("real worldâ€) studies on antipsychotics tell us the real truth?. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 257-270.	3.2	33
314	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 25-39.	3.2	33
315	Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatry Research - Neuroimaging, 2013, 211, 251-256.	1.8	33
316	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research, 2014, 152, 478-486.	2.0	33
317	5-HT2A SNPs and the Temperament and Character Inventory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1275-1281.	4.8	32
318	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 335-344.	3.2	32
319	Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. Journal of Affective Disorders, 2008, 108, 271-278.	4.1	32
320	Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. Expert Opinion on Drug Safety, 2010, 9, 683-697.	2.4	32
321	Prefrontal Cortex Modulation of Mood and Emotionally Induced Facial Expressions. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 206-212.	1.8	31
322	ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in Schizophrenia. NeuroImmunoModulation, 2005, 12, 54-59.	1.8	31
323	Design of Clinical Trials of Antidepressants. CNS Drugs, 2001, 15, 755-764.	5.9	30
324	Classification of Functional Psychoses and Its Implication for Prognosis: Comparison between ICD-10 and DSM-IV. Psychopathology, 2004, 37, 110-117.	1.5	30

#	Article	IF	CITATIONS
325	Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 2009, 19, 843-851.	1.5	30
326	Switch to Mania After Slow rTMS of the Right Prefrontal Cortex. Journal of Clinical Psychiatry, 2002, 63, 249.	2.2	30
327	Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. Journal of Affective Disorders, 2004, 83, 237-242.	4.1	29
328	Disentangling the adult attention-deficit hyperactivity disorder endophenotype: Parametric measurement of attention Journal of Abnormal Psychology, 2011, 120, 890-901.	1.9	29
329	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 694-698.	1.4	29
330	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 44-48.	3.2	28
331	Attitude towards adherence in patients with schizophrenia at discharge. Journal of Psychiatric Research, 2009, 43, 1294-1301.	3.1	28
332	The free choice whether or not to respond after stimulus presentation. Human Brain Mapping, 2009, 30, 2971-2985.	3.6	28
333	Bipolar disorder and schizophrenia: distinct illnesses or a continuum?. Journal of Clinical Psychiatry, 2003, 64 Suppl 6, 23-7; discussion 28.	2.2	28
334	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 3-16.	3.2	27
335	Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: Valid predictors of symptomatic response and remission?. World Journal of Biological Psychiatry, 2010, 11, 729-738.	2.6	27
336	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World Journal of Biological Psychiatry, 2010, 11, 36-44.	2.6	27
337	Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome. Current Psychiatry Reports, 2012, 14, 229-236.	4.5	27
338	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. European Neuropsychopharmacology, 2013, 23, 887-894.	0.7	27
339	EEG correlates of visual short-term memory as neuro-cognitive endophenotypes of ADHD. Neuropsychologia, 2016, 85, 91-99.	1.6	27
340	Corpus callosum and P300 in schizophrenia. Schizophrenia Research, 2001, 49, 107-119.	2.0	26
341	GABA _A receptors as targets for novel anxiolytic drugs. World Journal of Biological Psychiatry, 2006, 7, 231-237.	2.6	26
342	Response trajectories in "real-world―naturalistically treated schizophrenia patients. Schizophrenia Research, 2012, 139, 218-224.	2.0	26

#	Article	IF	CITATIONS
343	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 107-116.	3.2	26
344	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. World Journal of Biological Psychiatry, 2015, 16, 483-501.	2.6	26
345	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequencesâ€"part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessiveâ€"compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. European Archives of Psychiatry	3.2	26
346	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World Journal of Biological Psychiatry, 2019, 20, 2-16.	2.6	26
347	Problems associated with the classification and diagnosis of psychiatric disorders. World Journal of Biological Psychiatry, 2005, 6, 45-56.	2.6	25
348	Evidence of agomelatine's antidepressant efficacy: the key points. International Clinical Psychopharmacology, 2007, 22, S15-S19.	1.7	25
349	Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. Journal of Psychiatric Research, 2003, 37, 145-153.	3.1	24
350	Long-acting risperidone: Focus on safety. Clinical Therapeutics, 2006, 28, 633-651.	2.5	24
351	ABCG1 gene variants in suicidal behavior and aggression-related traits. European Neuropsychopharmacology, 2007, 17, 410-416.	0.7	24
352	Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Research, 2008, 158, 297-305.	3.3	24
353	Agomelatine: The evidence for its place in the treatment of depression. Core Evidence, 2010, 4, 171.	4.7	24
354	Does Clinical Judgment of Baseline Severity and Changes in Psychopathology Depend on the Patient Population?. Journal of Clinical Psychopharmacology, 2010, 30, 726-731.	1.4	24
355	Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. Journal of Psychopharmacology, 2012, 26, 744-750.	4.0	24
356	Glutamatergic Dysbalance and Oxidative Stress in In Vivo and In Vitro Models of Psychosis Based on Chronic NMDA Receptor Antagonism. PLoS ONE, 2013, 8, e59395.	2.5	24
357	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. International Journal of Psychiatry in Clinical Practice, 2015, 19, 158-167.	2.4	24
358	Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases. Schizophrenia Research, 1996, 20, 181-186.	2.0	23
359	In vivo effects of olanzapine on striatal dopamine D 2 /D 3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 862-868.	6.4	23
360	Handedness and corpus callosum morphology. Psychiatry Research - Neuroimaging, 2002, 116, 33-42.	1.8	23

#	Article	IF	CITATIONS
361	Novel Antipsychotics in the Long-term Treatment of Schizophrenia. World Journal of Biological Psychiatry, 2004, 5, 9-19.	2.6	23
362	Cincinnati criteria for mixed mania and suicidality in patients with acute mania. Comprehensive Psychiatry, 2004, 45, 62-69.	3.1	23
363	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [1231]IBZM SPECT. Psychiatry Research - Neuroimaging, 2009, 173, 183-189.	1.8	23
364	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. Journal of Psychiatric Research, 2010, 44, 487-492.	3.1	23
365	A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRGN rs12807809. Schizophrenia Research, 2011, 125, 304-306.	2.0	23
366	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. World Journal of Biological Psychiatry, 2012, 13, 30-38.	2.6	23
367	Multivariate patterns of brain–cognition associations relating to vulnerability and clinical outcome in the atâ€risk mental states for psychosis. Human Brain Mapping, 2012, 33, 2104-2124.	3.6	23
368	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 1: general aspects and paradigmatic discussion of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 5-18.	3.2	23
369	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. International Journal of Psychiatry in Clinical Practice, 2015, 19, 2-7.	2.4	23
370	Markers from event-related potential subcomponents and reaction time for information processing dysfunction in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 307-313.	3.2	22
371	Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 217-224.	3.2	22
372	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. Journal of Psychiatric Research, 2002, 36, 131-135.	3.1	22
373	Investigation of a possible diencephalic pathology in schizophrenia. Psychiatry Research - Neuroimaging, 2002, 115, 127-135.	1.8	22
374	How to grade categories of evidence. World Journal of Biological Psychiatry, 2008, 9, 242-247.	2.6	22
375	Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. Journal of Psychiatric Research, 2011, 45, 1639-1647.	3.1	22
376	State of the Art: Treatment of Bipolar Disorders. CNS Neuroscience and Therapeutics, 2012, 18, 214-218.	3.9	22
377	Obsessive-compulsive disorder – A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. Journal of Psychiatric Research, 2015, 68, 354-362.	3.1	22
378	Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. Journal of Affective Disorders, 2015, 173, 126-133.	4.1	22

#	Article	IF	CITATIONS
379	Anxiolytic Effects of Vigabatrin in Panic Disorder. Journal of Clinical Psychopharmacology, 2001, 21, 539-540.	1.4	22
380	Familial Cosegregation of Affective Disorder and Hailey-Hailey Disease. British Journal of Psychiatry, 1993, 163, 109-110.	2.8	21
381	In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: New findings and comparison with the literature. Schizophrenia Research, 2007, 96, 34-45.	2.0	21
382	The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 7-17.	3.2	21
383	Antidepressants: Controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World Journal of Biological Psychiatry, 2009, 10, 180-195.	2.6	21
384	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 13-22.	3.2	21
385	Genetics of emergent suicidality during antidepressive treatment—Data from a naturalistic study on a large sample of inpatients with a major depressive episode. European Neuropsychopharmacology, 2013, 23, 663-674.	0.7	21
386	Duloxetine: a new selective and dual-acting antidepressant. Expert Opinion on Pharmacotherapy, 2006, 7, 421-427.	1.8	20
387	Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. International Journal of Neuropsychopharmacology, 2008, 11, 477-83.	2.1	20
388	Reception of Kraepelin's ideas 1900–1960. Psychiatry and Clinical Neurosciences, 2011, 65, 318-325.	1.8	20
389	Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 85-92.	3.2	20
390	Mobility behaviour and driving status of patients with mental disorders – an exploratory study. International Journal of Psychiatry in Clinical Practice, 2016, 20, 40-46.	2.4	20
391	Electroencephalography as a Diagnostic Instrument in Alzheimer's Disease: Reviews and Perspectives. International Psychogeriatrics, 1997, 9, 237-246.	1.0	19
392	Deficit states in schizophrenia and their association with the length of illness and gender. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 272-278.	3.2	19
393	Metaanalyses—highest level of empirical evidence?. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 369-370.	3.2	19
394	Remission and Recovery and their Predictors in Schizophrenia Spectrum Disorder: Results from a 1-Year Follow-Up Naturalistic Trial. Psychiatric Quarterly, 2012, 83, 187-207.	2.1	19
395	A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. Schizophrenia Bulletin, 2016, 42, S71-S80.	4.3	19
396	Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. Microbial Biotechnology, 2016, 10, 17-27.	1.7	19

#	Article	IF	CITATIONS
397	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1Âyear after their first in-patient treatment. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 459-468.	3.2	19
398	Silexan in generalized anxiety disorder. International Clinical Psychopharmacology, 2017, 32, 195-204.	1.7	19
399	Do Efficacy and Effectiveness Samples Differ in Antidepressant Treatment Outcome?. Journal of Clinical Psychiatry, 2010, 71, 1425-1433.	2.2	19
400	The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia. Current Opinion in Psychiatry, 2003, 16, S39-S43.	6.3	18
401	Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. International Clinical Psychopharmacology, 2008, 23, 95-105.	1.7	18
402	Prediction of symptom remission in schizophrenia during inpatient treatment. World Journal of Biological Psychiatry, 2009, 10, 426-434.	2.6	18
403	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 405-412.	3.2	18
404	Neuropsychological functioning in inpatients with major depression or schizophrenia. BMC Psychiatry, 2013, 13, 203.	2.6	18
405	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 757-761.	1.7	17
406	Meta-analyses: a method to maximise the evidence from clinical studies?. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 17-23.	3.2	17
407	Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI. Cortex, 2011, 47, 569-574.	2.4	17
408	Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 3-10.	3.2	17
409	Attention to emotion: auditory-evoked potentials in an emotional choice reaction task and personality traits as assessed by the NEO FFI. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 111-120.	3.2	17
410	Are the new antipsychotics no better than the classical neuroleptics?. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 371-372.	3.2	16
411	Fifteen-year follow-up of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorders: the prognostic significance of psychotic features. Comprehensive Psychiatry, 2005, 46, 322-327.	3.1	16
412	Distinct seasonality of depressive episodes differentiates unipolar depressive patients with and without depressive mixed states. Journal of Affective Disorders, 2006, 90, 1-5.	4.1	16
413	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 308-315.	1.7	16
414	Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 49-59.	1.8	16

#	Article	IF	CITATIONS
415	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World Journal of Biological Psychiatry, 2010, 11, 447-456.	2.6	16
416	Schizotypy and Behavioural Adjustment and the Role of Neuroticism. PLoS ONE, 2012, 7, e30078.	2.5	16
417	The media and intellectuals' response to medical publications: the anti-depressants' case. Annals of General Psychiatry, 2013, 12, 11.	2.7	16
418	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 65-74.	3.2	16
419	Intact emotion–cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. Brain and Cognition, 2013, 82, 329-336.	1.8	16
420	Corpus Callosum Measurement as an <i>in Vivo</i> Indicator for Neocortical Neuronal Integrity, but not White Matter Pathology, in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 470-476.	3.8	15
421	Improving the chance of recovery from the short- and long-term consequences of depression. International Clinical Psychopharmacology, 2003, 18, 219-225.	1.7	15
422	Creating a map of psychiatric patients based on psychopathological symptom profiles. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 164-171.	3.2	15
423	Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 227-238.	3.2	15
424	Drug Treatment of Depressive Symptoms in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2008, 1, 328-340.	1.4	15
425	Biological Perspectives on Psychiatry for the Person. International Journal of Person Centered Medicine, 2011, 1, 137-139.	0.2	15
426	Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression. Acta Neuropsychiatrica, 2003, 15, 217-226.	2.1	14
427	Kinematical Analysis of Motor Function in Schizophrenic Patients: a Possibility to Separate Negative Symptoms from Extrapyramidal Dysfunction Induced by Neuroleptics?. Pharmacopsychiatry, 2004, 37, 110-118.	3.3	14
428	Influence of Anxiety on Electrophysiological Correlates of Response Inhibition Capacities in Alcoholism. Clinical EEG and Neuroscience, 2007, 38, 89-95.	1.7	14
429	Estrogen receptor gene 1 variants are not associated with suicidal behavior. Psychiatry Research, 2008, 160, 1-7.	3.3	14
430	Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms. Psychiatry Research - Neuroimaging, 2010, 183, 133-139.	1.8	14
431	Antipsychotic Response in the First Week Predicts Later Efficacy. Neuropsychobiology, 2012, 66, 100-105.	1.9	14
432	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. Cognitive Neuropsychiatry, 2017, 22, 280-297.	1.3	14

#	Article	IF	CITATIONS
433	The German Research Network on Schizophreniaimpact on the management of schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 115-121.	3.7	14
434	White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 278-284.	3.2	13
435	EDITORIAL. World Journal of Biological Psychiatry, 2008, 9, 82-85.	2.6	13
436	A proposal for a psychopharmacology–pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World Journal of Biological Psychiatry, 2017, 18, 29-38.	2.6	13
437	NCAM1, TACR1 and NOS Genes and Temperament: A Study on Suicide Attempters and Controls. Neuropsychobiology, 2011, 64, 32-37.	1.9	12
438	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. International Journal of Psychiatry in Clinical Practice, 2014, 18, 78-85.	2.4	12
439	Brofaromine versus imipramine in in-patients with major depression – a controlled trial. Journal of Affective Disorders, 1997, 44, 91-99.	4.1	11
440	Translations of Measurements and Scales: Opportunities and Diversities. International Psychogeriatrics, 2000, 12, 391-394.	1.0	11
441	Platelet Monoamine Oxidase Activity in Alcoholics with and without a Family History of Alcoholism. European Addiction Research, 2000, 6, 57-63.	2.4	11
442	Chapter 42 Prefrontal cortex stimulation as antidepressant treatment: mode of action and clinical effectiveness of rTMS. Supplements To Clinical Neurophysiology, 2003, 56, 406-432.	2.1	11
443	[123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. European Archives of Psychiatry and Clinical Neuroscience, 2007, 258, 40-47.	3.2	11
444	SNAP-25 genotype influences NAA/Cho in left hippocampus. Journal of Neural Transmission, 2008, 115, 1513-1518.	2.8	11
445	Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. Methods, 2012, 56, 519-527.	3.8	11
446	Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. BMC Medicine, 2012, 10, 67.	5.5	11
447	Interference control in adult ADHD: No evidence for interference control deficits if response speed is controlled by delta plots. Acta Psychologica, 2013, 143, 71-78.	1.5	11
448	Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. NeuroImage: Clinical, 2019, 21, 101624.	2.7	11
449	Therapy resistance/chronicity, their determinants and potential solutions. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 1-2.	3.2	11
450	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 434-438.	1.7	10

#	Article	IF	CITATIONS
451	Antidepressants and suicidality in younger adults – is bipolar illness the missing link?. Acta Psychiatrica Scandinavica, 2009, 119, 166-166.	4.5	10
452	Cardiovascular disease and diabetes in people with severe mental illness. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 49-59.	0.3	10
453	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. Psychiatry Research, 2010, 179, 222-225.	3.3	10
454	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 190-195.	4.8	10
455	Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study. Psychiatry Research - Neuroimaging, 2016, 249, 84-90.	1.8	10
456	The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?. Psychiatria Danubina, 2016, 28, 435-440.	0.4	10
457	Brofaromine. CNS Drugs, 1995, 3, 1-8.	5.9	9
458	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. Revista De Psiquiatria Clinica, 2006, 33, 7-64.	0.6	9
459	Is evidence sufficient for evidence-based medicine?. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 167-172.	3.2	9
460	Infectious agents are associated with psychiatric diseases. Mental Illness, 2012, 4, 38-42.	0.8	9
461	Driving Ability According to German Guidelines in Stabilized Bipolar I and II Outpatients Receiving Lithium or Lamotrigine. Journal of Clinical Pharmacology, 2013, 53, 459-462.	2.0	9
462	A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients ―Results from the German Algorithm Project (GAP3). Journal of Affective Disorders, 2018, 228, 173-177.	4.1	9
463	The ongoing discussion on termination of life on request. A review from a German/European perspective. International Journal of Psychiatry in Clinical Practice, 2021, 25, 2-18.	2.4	9
464	Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders. Psychiatria Polska, 2018, 52, 611-628.	0.5	9
465	Viewpoint: Methodological Issues in Psychiatry: Psychiatry as an Empirical Science. World Journal of Biological Psychiatry, 2001, 2, 38-47.	2.6	8
466	Study design features affecting outcome in antidepressant trials. Journal of Affective Disorders, 2012, 141, 160-167.	4.1	8
467	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm― International Journal of Psychiatry in Clinical Practice, 2013, 17, 78-89.	2.4	8
468	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 303-313.	3.2	8

#	Article	IF	CITATIONS
469	Driving ability in schizophrenic patients: effects of neuroleptics. International Journal of Psychiatry in Clinical Practice, 2005, 9, 168-174.	2.4	7
470	Tyrosine Hydroxylase and DOPA Decarboxylase Gene Variants in Personality Traits. Neuropsychobiology, 2009, 59, 23-27.	1.9	7
471	How close is evidence to truth in evidence-based treatment of mental disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 277-289.	3.2	7
472	Are antidepressants clinically useful? Conclusion of a decade of debate. World Psychiatry, 2014, 13, 201-202.	10.4	7
473	Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 385-386.	3.2	7
474	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin's Former Hospital. Schizophrenia Bulletin, 2016, 42, S81-S89.	4.3	7
475	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. BMC Psychiatry, 2016, 16, 153.	2.6	7
476	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world―2-year follow-up trial. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 661-671.	3.2	7
477	No Association of a Set of Candidate Genes on Haloperidol Side Effects. PLoS ONE, 2012, 7, e44853.	2.5	7
478	Ethical aspects of publishing. World Journal of Biological Psychiatry, 2006, 7, 66-69.	2.6	6
479	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 74-77.	4.8	6
480	Antidepressants vs. placebo: not merely a quantitative difference in response. International Journal of Neuropsychopharmacology, 2011, 14, 1435-1437.	2.1	6
481	Critical trial-related criteria in acute schizophrenia studies. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 151-155.	3.2	6
482	Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study. Journal of Affective Disorders, 2018, 238, 570-578.	4.1	6
483	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. International Journal of Neuropsychopharmacology, 2021, 24, 171-180.	2.1	6
484	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. Journal of Affective Disorders, 2022, 299, 73-84.	4.1	6
485	The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia. International Journal of Psychiatry in Clinical Practice, 1997, 1, 59-67.	2.4	5
486	Saccadic Eye Velocity after Selective GABAergic Treatment with Tiagabine in Healthy Volunteers. Neuropsychobiology, 2005, 52, 147-150.	1.9	5

#	Article	IF	CITATIONS
487	Are placebo-controlled studies required in order to prove efficacy of antidepressants?. World Journal of Biological Psychiatry, 2005, 6, 130-131.	2.6	5
488	Psychopathology: genetics and the stress-vulnerability hypothesis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 181-182.	3.2	5
489	Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods. International Journal of Methods in Psychiatric Research, 2016, 25, 3-11.	2.1	5
490	Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. Schizophrenia Research, 2019, 209, 185-192.	2.0	5
491	Predictors of treatment response to psychological interventions in people at clinical high risk of firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 120-127.	1.7	5
492	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. International Journal of Psychiatry in Clinical Practice, 2022, 26, 277-286.	2.4	5
493	Effects of different antidepressant treatments on the core of depression. Dialogues in Clinical Neuroscience, 2008, 10, 309-320.	3.7	5
494	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. Human Psychopharmacology, 1998, 13, 43-51.	1.5	4
495	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. Archives of Suicide Research, 1998, 4, 143-155.	2.3	4
496	SSRIs: Are the accusations justified. World Journal of Biological Psychiatry, 2004, 5, 174-175.	2.6	4
497	The influence of 4–week treatment with sertraline on the combined T3/TRH test in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 334-340.	3.2	4
498	The assessment of cognitive impairment would be a relevant addition to the criteria for diagnosing schizophrenia. World Psychiatry, 2008, 7, 35-36.	10.4	4
499	The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. World Journal of Biological Psychiatry, 2013, 14, 386-395.	2.6	4
500	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. Journal of Psychiatric Research, 2021, 136, 543-551.	3.1	4
501	Is the Overlap of Neurobiological and Psychopathological Parameters: Large Enough to Give up the Dichotomic Classification?. Psychiatric Annals, 2010, 40, 163-167.	0.1	4
502	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 51-63.	3.2	4
503	Do effectiveness studies tell us the real truth?. World Journal of Biological Psychiatry, 2007, 8, 138-140.	2.6	3
504	Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years. Evidence-Based Mental Health, 2010, 13, 52-52.	4.5	3

#	Article	IF	CITATIONS
505	Pharmacotherapy of Schizophrenic Patients: Achievements, Unsolved Needs, Future Research Necessities. Current Pharmaceutical Biotechnology, 2012, 13, 1476-1489.	1.6	3
506	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?. Pharmacopsychiatry, 2017, 50, 136-144.	3.3	3
507	Polymorphisms in CRYBB2 encoding βB2-crystallin are associated with antisaccade performance and memory function. Translational Psychiatry, 2020, 10, 113.	4.8	3
508	Dementia Treatment: A German Perspective on Psychosocial Aspects and Therapeutic Approaches. International Psychogeriatrics, 1995, 7, 459-470.	1.0	2
509	Is lithium still the gold standard in the treatment of bipolar disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 113-114.	3.2	2
510	Access to The World Journal of Biological Psychiatry. World Journal of Biological Psychiatry, 2004, 5, 118-119.	2.6	2
511	Safety evaluation of zotepine for the treatment of schizophrenia. Expert Opinion on Drug Safety, 2010, 9, 659-666.	2.4	2
512	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. Psychopharmacology, 2011, 214, 719-728.	3.1	2
513	Why are new antidepressants failing to make the grade for approval?. Expert Opinion on Pharmacotherapy, 2017, 18, 641-643.	1.8	2
514	Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 525-527.	3.2	2
515	Medication management of antipsychotic treatment in schizophrenia—A narrative review. Human Psychopharmacology, 2021, 36, e2765.	1.5	2
516	Involvement of mesial-temporal structures in rapid cycling mood disorders?. Human Psychopharmacology, 1995, 10, 475-480.	1.5	1
517	The problem of being a paradigm: the emergence of neural stem cells as example for "Kuhnian― revolution in biology or misconception of the scientific community?. Poiesis & Praxis, 2009, 6, 3-11.	0.3	1
518	Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions. Journal of Clinical Psychopharmacology, 2011, 31, 120-122.	1.4	1
519	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. Focus (American Psychiatric Publishing), 2011, 9, 500-525.	0.8	1
520	New aspects of the vulnerability stress model in general, its relevance in schizophrenic psychoses and the place of antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 485-486.	3.2	1
521	Classification Systems of Mental Disorders: Where Did We Go Wrong?. , 2020, , 193-203.		1

#	Article	IF	CITATIONS
523	Side effect burden of antipsychotic medication. Medical Psychiatry, 2009, , 231-259.	0.2	1
524	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs). , 1993, , 163-182.		1
525	Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identitä Situation und Perspektiven eines großen medizinischen Fachgebietes. , 2016, , 1-35.		1
526	Psychopharmakotherapie â \in " klinisch-empirische Grundlagen. , 2017, , 795-842.		1
527	Propentofylline. CNS Drugs, 1997, 8, 265.	5.9	0
528	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. Archives of Suicide Research, 1998, 4, 143-155.	2.3	0
529	Viewpoint: Past, Present and Future of Biological Psychiatry. World Journal of Biological Psychiatry, 2001, 2, 156-158.	2.6	0
530	Response to letter to the editor from Andrade et al. (2003) ECT in the management of major depression: Implications of recent research, World J Biol Psychiatry 4: 139-140. World Journal of Biological Psychiatry, 2003, 4, 140-141.	2.6	0
531	Do "real world―studies on antipsychotics tell us the real truth?. World Psychiatry, 2009, 8, 32-32.	10.4	0
532	The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics. Annals of General Psychiatry, 2010, 9, .	2.7	0
533	From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 275-276.	3.2	0
534	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. Pharmacopsychiatry, 2019, 52, 180-185.	3.3	0
535	The place of comorbidity and of subtle psychopathological evaluation. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 939-940.	3.2	0
536	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
537	Schizoaffektive Psychosen und sonstige wahnhafte Störungen nicht organischer Genese. , 2004, , 160-188.		0
538	Schizophrene Psychosen. , 2004, , 109-160.		0
539	Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie. , 2004, , 19-60.		0
540	Evaluación clÃnica de los sÃntomas negativos de la esquizofrenia. European Psychiatry (Ed Española), 2007, 14, 375-382.	0.0	0

0

#	Article	IF	CITATIONS
541	Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen. , 2010, , 187-196.		0
542	Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients. , 2011, , 93-107.		0
543	Suicidality and Outcome in Schizophrenia Patients. , 2011, , 365-382.		0
544	Psychiatrie in Europa: Stand der Dinge, Chancen und Herausforderungen. , 2012, , 219-227.		0
545	Antipsychotic Treatment Within a Naturalistic Trial—How Are We Treating Schizophrenia Patients in the "Real-World�. , 2013, , 137-156.		0
546	In Reply. Deutsches Ärzteblatt International, 2013, 110, 610-1.	0.9	0
547	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2015, , 1-28.		0
548	Standardisierte Befunddiagnostik in der Psychiatrie. , 2015, , 1-25.		0
549	Psychiatric Assessment: Negative Symptoms. , 2015, , 290-294.		0
550	Evidenzbasierung und leitliniengesch $ ilde{A}^{1\!/\!4}$ tzte Therapie in der Psychiatrie. , 2016, , 1-18.		0
551	Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identitä, Situation und Perspektiven eines großen medizinischen Fachgebietes. , 2017, , 3-37.		0
552	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. , 2017, , 1321-1338.		0
553	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2017, , 463-490.		0
554	Standardisierte Befunddiagnostik in der Psychiatrie. , 2017, , 577-600.		0
555	Schizophrene und schizophreniforme Störungen. , 2005, , 1342-1351.		0

556 Schizophrene und schizophreniforme StÄ \P rungen. , 2007, , 1507-1518.